Details of the Drug
General Information of Drug (ID: DMWLFGO)
| Drug Name |
Methyltestosterone
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | Android (TN) | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Indication |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| ATC Code |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Structure |
![]() |
|||||||||||||||||||||||||||||||||||||||||||||||||||
| 3D MOL | 2D MOL | |||||||||||||||||||||||||||||||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 302.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 3.4 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| ADMET Property |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Chemical Identifiers |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Cross-matching ID | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Pharmacogenomic Perturbation (DPP)NEW | Click to Jump to the Detailed DPP Information of This Drug | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug ADMET Endpoint Profile (DAE)NEW | Click to Jump to the Detailed DAE Information of This Drug | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Repurposed Drugs (RPD) | Click to Jump to the Detailed RPD Information of This Drug | |||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug-Metabolizing Enzyme (DME) |
|
||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
![]() Drug Off-Target (DOT) |
|
||||||||||||||||||||||||||||||
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||
Drug-Drug Interaction (DDI) Information of This Drug
|
Coadministration of a Drug Treating the Disease Different from Methyltestosterone (Comorbidity)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
| 1 | Methyltestosterone FDA Label | ||||
|---|---|---|---|---|---|
| 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6945). | ||||
| 3 | Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds | ||||
| 4 | Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes. Gas chromatographic-mass spectrometric determination of metabolites. J Chromatogr B Biomed Sci Appl. 1999 Nov 26;735(1):73-83. | ||||
| 5 | Hepatic expression patterns of aryl hydrocarbon receptor, pregnane X receptor, two cytochrome P450s and five phase II metabolism genes responsive to 17alpha-methyltestosterone in rare minnow Gobiocypris rarus. Environ Toxicol Pharmacol. 2014 May;37(3):1157-68. | ||||
| 6 | Evaluation of an imaging-based in vitro screening platform for estrogenic activity with OECD reference chemicals. Toxicol In Vitro. 2022 Jun;81:105348. doi: 10.1016/j.tiv.2022.105348. Epub 2022 Mar 18. | ||||
| 7 | Cerner Multum, Inc. "Australian Product Information.". | ||||
| 8 | Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ. | ||||
| 9 | Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ. | ||||
| 10 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||
| 11 | Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA. | ||||
| 12 | Canadian Pharmacists Association. | ||||
| 13 | Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA. | ||||
| 14 | Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500] | ||||
| 15 | Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA. | ||||
| 16 | Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792] | ||||



